Clinical Trials Logo

Prader-Willi Syndrome clinical trials

View clinical trials related to Prader-Willi Syndrome.

Filter by:

NCT ID: NCT03440814 Completed - Clinical trials for Prader-Willi Syndrome

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

Start date: May 9, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.

NCT ID: NCT03274856 Completed - Clinical trials for Prader-Willi Syndrome

A Study of GLWL-01 in Patients With Prader-Willi Syndrome

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate efficacy, safety, and pharmacokinetics of GLWL-01 in the treatment of patients with Prader-Willi Syndrome (PWS).

NCT ID: NCT03245762 Completed - Clinical trials for Prader-Willi Syndrome

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

Start date: August 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to compare the change in suck and swallow competency from baseline to morning of day 6 with intranasal oxytocin spray vs placebo in infants/children with Prader-Willi Syndrome who are in nutritional phase 1a. Videofluoroscopic swallow studies will be performed on treatment day 1 and on the day following treatment morning of day 6.

NCT ID: NCT03149445 Completed - Clinical trials for Confirmed Genetic Diagnosis of Prader-Willi Syndrome

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

2016-003694-18
Start date: March 30, 2017
Phase: Phase 2
Study type: Interventional

Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study followed by two open label extension periods.

NCT ID: NCT03114371 Completed - Clinical trials for Prader-Willi Syndrome

Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years

Oxyjeune
Start date: November 28, 2016
Phase: N/A
Study type: Interventional

Positive results in preclinical and clinical studies in adults and infants with Prader-Willi syndrome lead investigators to set up a new study in children with Prader-Willi syndrome. The objective of this study is to document effects of oxytocin intranasal administrations on behavioural troubles in children with Prader-Willi syndrome aged from 3 to 12 years.

NCT ID: NCT03081832 Completed - Clinical trials for Prader-Willi Syndrome

Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.

OT2SUITE
Start date: January 2017
Phase: N/A
Study type: Interventional

The objective of this study is to collect data on tolerance and effects of early treatment with oxytocin in children with Prader Willi Syndrome aged from 3 to 4 years and to compare these infants with not treated age-matched infants with Prader Willi Syndrome.

NCT ID: NCT02804373 Completed - Clinical trials for Prader-Willi Syndrome

Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome

PRADOTIM
Start date: June 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The investigator thinks that the oxytocin (OT) can improve durably and significantly the behavior disorders and thus the socialization but also the satisfaction and could thus be an interesting therapeutic alternative for the patients presenting a Prader-Willi Syndrome (SPW). Although today several studies demonstrated the effects of the OT in various domains of the behavior, the investigator do not know either its specificity of action about the cerebral level, or its duration of action, or the optimal modalities of administration and in particular at patients SPW.

NCT ID: NCT02670694 Completed - Clinical trials for Prader-Willi Syndrome

Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW

RDCRN
Start date: June 2011
Phase: N/A
Study type: Observational

This study will investigate sleep behavior in subjects with Angelman Syndrome, Rett Syndrome or Prader-Willi Syndrome. The study will also investigate sleep behavior in healthy siblings of subjects with Angelman Syndrome, Rett Syndrome or Prader-Willi Syndrome. These individuals will serve as control subjects. The study will use questionnaires designed to identify sleep disorders and how they affect behavior and quality of life. The principal goals of this study are: 1. To see how common sleep disorders are in individuals with Angelman Syndrome, Rett Syndrome or Prader-Willi Syndrome; 2. To see how sleep disorders affect behavior in these individuals; 3. To see whether sleep disorders and related behavior problems improve or worsen with age; 4. To see how specific disease conditions relate to sleep disorders and how bad the sleep disorders are; 5. To develop new treatment options to improve quality of life and behavior issues; and 6. To evaluate current treatment options to improve sleep problems in these individuals.

NCT ID: NCT02629991 Completed - Clinical trials for Prader-Willi Syndrome

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

OXT-PWS
Start date: October 2015
Phase: Phase 2
Study type: Interventional

The investigators propose a randomized double-blind 8 week treatment trial of intranasal oxytocin (IN-OXT) vs. placebo in 24 subjects aged 5 to 18 years with PWS in order to assess IN-OXT's affect on (1) Eating behaviors (2) Repetitive and disruptive behaviors and (3) Salivary OXT levels.

NCT ID: NCT02529085 Completed - Clinical trials for Prader-Willi Syndrome

PWS European Blood Bank for Infants and Controls From 0 to 48 Months

Start date: March 2013
Phase: N/A
Study type: Interventional

The present project aims to determine the underlying mechanisms for the switch from failure to thrive to excessive weight gain and hyperphagia with impaired satiety in PWS. The primary objective is to describe the evolution of circulating hormones involved in feeding and appetite regulation during the 4 first years of life. The secondary objective is to make this blood bank available for other research projects and particularly the investigation of hormones involved in hypogonadism. Over the last ten years, the age at diagnosis in PWS has fallen significantly and the majority of cases is now diagnosed during the 1st trimester of life giving the possibility to collect precise clinical data and serum samples at early stages. The investigators of the project are involved in the care of patients with PWS and have a devoted clinic and an organized network in their country through clinical networks or patient associations.